Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
ANN ARBOR, Mich. & CHICAGO--(BUSINESS WIRE)--Penrose TherapeuTx, a pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers, today welcomed Dr. Vicki Seyfert-Margolis, Chief Executive Officer and Founder of MyOwnMed, to its scientific advisory board. A prominent strategic advisor in regulatory science, Dr. Seyfert-Margolis has nearly two decades of experience at the U.S. Food and Drug Administration (FDA) and the National Institute of Health (NIH) where she worked closely with National Institute of Allergy and Infectious Diseases (NIAID) Director, Dr. Anthony Fauci. Dr. Seyfert-Margolis is the latest addition to a world-class scientific advisory board with experts who have contributed to the Nobel Prize and led groundbreaking oncology and mitochondrial research efforts.
“We are thrilled to welcome Dr. Seyfert-Margolis as the latest world-renowned expert to join our high-caliber team of scientific advisors,” said Mark de Souza, Chief Executive Officer at Penrose TherapeuTx. “Dr. Seyfert-Margolis is a respected regulatory and research expert, and her insights will be vital as we move forward in the next phase of development for our novel mitochondrial research platform.”
Dr. Seyfert-Margolis served as a Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the FDA during all eight years of the Obama Administration and two under the Trump Administration. She also served as the Director of the Office of Innovative Scientific Research Technologies at the NIAID, where she worked alongside Dr. Fauci to integrate emerging technologies into existing immunology and infectious disease programs. Additionally, Dr. Seyfert-Margolis worked as the Chief Scientific Officer at the Immune Tolerance Network (ITN), an international, nonprofit research consortium seeking new treatments for diseases of the immune system, which is supported by the NIAID and the National Institute of Diabetes and Digestive and Kidney Diseases, of the NIH, and the Juvenile Diabetes Research Foundation International.
Dr. Seyfert-Margolis joins an established advisory board of leading experts in oncology, immunology and mitochondrial science, including Navdeep Chandel, Ph.D., Professor of Medicine, Biochemistry and Molecular Genetics at the Northwestern University Feinberg School of Medicine, Mircea Ivan, Ph.D., M.D., Associate Professor of Medicine at the University of Indiana School of Medicine, David Rubin, M.D., Joseph B. Kirsner Professor Chair, Chief of the Section of Gastroenterology, Hepatology and Nutrition and Co-Director, Digestive Diseases Center at the University of Chicago Medicine, Patrick Farmer, Ph.D., Professor and Chair of the Department of Chemistry and Biochemistry at Baylor University and James Stankiewicz, M.D., Professor of Otolaryngology at the Loyola University Medical Center.
“I am excited to join Penrose’s scientific advisory board as the company moves ahead with a truly novel approach to fighting cancer,” said Dr. Vicki Seyfert-Margolis. “The mitochondrial approach to oncology therapy is one that is completely distinct from other therapies and incredibly promising.”
Dr. Seyfert-Margolis founded MyOwnMed, a clinical medical research organization focused on using real-world evidence to drive healthcare innovation, in 2013 as a way to optimize therapies for patients using a patient-centric technology-driven clinical research approach. She completed her Ph.D. in immunology at the University of Pennsylvania’s School of Medicine and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.
About Penrose TherapeuTx
Penrose TherapeuTx is a U.S.-based pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers. Penrose has pioneered the development of a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies for difficult to treat cancers through a unique cooperative mechanism of action. Our approach has potential broad applicability across both hematologic and solid tumors. Learn more at https://penrosetherapeutx.com.